HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis

Diagnostic Pathology

Table 3 Associations between HtrA1 tumoral expression and outcomes according to sub-cellular HtrA1 expression in women with high grade serous ovarian

Sub-cellular location	Methods, comparisons	Progression		Death
Sub-cellular location	Methods, comparisons	Crude HR (95% CI); P-value	Adjusted HR ^a (95% CI); P-value	Crude HR (95% CI); P-value	Adjusted HR ^a (95% CI); P-value
Nucleus	Visual ≤ 10.0 vs > 10.0	0.68 (0.45–1.04); 0.08	0.71 (0.46–1.09); 0.11	0.70 (0.45–1.10); 0.12	0.65 (0.41–1.04); 0.07
Nucleus	Digital < 36.4 vs ≥ 36.4	0.61 (0.40–0.93); 0.02**	0.62 (0.40–0.95); 0.03**	0.64 (0.41–1.00); 0.05	0.60 (0.38–0.95); 0.03**
Cytoplasm	Visual < 100.0 vs 100.0	1.08 (0.71–1.64); 0.72	1.08 (0.71–1.64); 0.71	0.70 (0.45–1.10); 0.12	0.65 (0.41–1.04); 0.07
Cytoplasm	Digital < 73.2 vs ≥ 73.2	0.84 (0.55–1.28); 0.41	0.82 (0.54–1.25); 0.35	0.90 (0.58–1.39); 0.62	0.84 (0.54–1.31); 0.43

Abbreviations: HR Hazard ratio, CI Confidence interval
^a Adjusted for FIGO stage (III-IV versus I-II), age at diagnosis (continuous) and pre-operative serum CA-125 levels (dichotomized according to the median value, ≥ 681.5 pmol/L versus < 681.5 pmol/L); ** P<0.05

ISSN: 1746-1596